Takeda entering a new era and transforming for growth acceleration
Japan’s largest drugmaker Takeda (TYO- 4502) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The company delivered solid results in line with its latest FY2025 management guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth.
Revenue of 4,505.7 billion yen ($28.55 billion) decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for Vyvanse (lisdexamfetamine), which was partially mitigated by growth and launch products. On a core basis, revenue decreased by 2.6% at constant exchange rate (CER).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze